Other Lung Path Flashcards
Sarcoidosis
Multisystem disease of unknown etiology characterized by noncaseating granulomas in many tissues and organs
Bilateral hilar lymphadenopathy and/or lung involvement is the major presenting manifestation in most cases
Epidemiology
-Adults younger than 40
-Danish, Swedish, African Americans (10x)
-Higher prevalence even in non-smokers
Sarcoidosis path
Disordered immune regulation in genetically predisposed individuals exposed to certain environmental agents
Process is driven by TH1 cells
Sarcoidosis morphology
Noncaseating epithelioid granulomas
Many organs involved
-Lungs: involved at some point in 90% of patients; in 5-15% of patients granulomas are eventually replaced by diffuse interstitial fibrosis
-Hilar and paratracheal lymph nodes enlarged in 75-90%
-Skin, eye, lacrimal glands, salivary glands
-Spleen, liver, bone marrow
Sarcoidosis clinical
Many individuals are entirely asymptomatic
In symptomatic cases,
-2/3 have respiratory symptoms (shortness of breath, dry cough, substernal discomfort) or constitutional symptoms (fever, fatigue, weight loss, anorexia, night sweats)
Unpredictable course
-Progressive chronicity or periods of activity and remission
-65-70% recover with minimal to no residual effects
-20% develop permanent lung dysfunction or visual impairment
-15-20% die from progressive pulmonary fibrosis and cor pulmonale
Hypersensitivity Pneumonitis
Allergic alveolitis
Immunologically mediated inflammatory lung disease that primarily affects the alveoli
-Immune complex and delayed-type hypersensitivity reactions
-2/3 have interstitial noncaseating granulomas
Heightened sensitivity to inhaled antigens
-Most often an occupational disease
Hypersensitivity Pneumonitis clinical
Acute reaction
-Fever, cough, dyspnea, constitutional complaints 4-8 hours after exposure
-Complete remission, if antigen exposure is terminated
Chronic disease
-Insidious onset of cough, dyspnea, malaise, weight loss
-If antigen is not removed, chronic interstitial disease develops without the acute exasperations on antigen re-exposure
Pulmonary Eosinophilia
Entities characterized by an infiltration and activation of eosinophils
-Generally immunologic in origin, but poorly understood
Acute eosinophilic pneumonia with respiratory failure
-Rapid onset of fever, dyspnea, hypoxia, and diffuse pulmonary infiltrates
-Bronchioalveolar lavage fluid contains >25% eosinophils
-Prompt response to steroids
Pulmonary Eosinophilia
Simple pulmonary eosinophilia (Löffler syndrome)
- Transient pulmonary lesions and blood eosinophilia
- Alveolar septal infiltrate of eosinophils
- Benign clinical course
Tropical eosinophilia
-Microfilariae infestation
Secondary eosinophilia
-Asthma, drug allergies, vasculitis
Idiopathic chronic eosinophilic pneumonia
- Aggregates of lymphocytes and eosinophils in alveolar septa and airspaces
- High fever, night sweats, dyspnea
- Disease of exclusion
Smoking Related Interstitial Diseases
Desquamative interstitial pneumonia (DIP)
- Accumulation of large numbers of macrophages in the airspaces
- Good prognosis
- Excellent response to steroids and smoking cessation
Respiratory bronchiolitis
-Similar histology to DIP but centered on respiratory bronchioles
Clinical
- Gradual onset of dyspnea and dry cough
- Symptoms recede with smoking cessation
Pulmonary Thromboembolism
95% arise from thrombi within the deep veins of the legs Risk factors Prolonged bedrest Surgery Severe trauma Congestive heart failure Around childbirth High estrogen birth control pills Disseminated cancer Primary hypercoagulability disorders
Pulmonary Thromboembolism
Pathophysiologic consequences depend upon the size of the embolus and the cardiopulmonary status of the patient
-Increase in pulmonary artery pressure from occlusion and possibly vasospasm
-Ischemia of down-stream lung tissue
-Hypoxia
Infarct of lung occurs in only about 10% of cases
-Depends on size of vessel occluded, status of bronchial circulation and cardiac function, ventilation of effected lung region
Thromboemboli may cause virtually instantaneous death
Pulmonary Thromboembolism clinical course
Most emboli are clinically silent (60-80%)
-Embolus removed by fibrinolytic activity
-Lung viability is maintained
Sudden death, acute right-sided heart failure, or cardiovascular collapse (5%)
->60% of total pulmonary vasculature is obstructed
Obstruction of small to medium pulmonary branches (10-15%)
-Causes pulmonary infarction
Recurrent multiple emboli (<3%)
-Pulmonary hypertension, chronic right-sided heart failure, vascular sclerosis, worsening dyspnea
30% chance of having a second embolus after having a first
Pulmonary Thromboembolism Non-thrombotic emboli
Air, fat, amniotic fluid, foreign body, bone marrow
Talc in intravenous drug users
-Interstitial and vascular complications
Pulmonary Hypertension
Pulmonary hypertension occurs when mean pulmonary pressures reach ¼ systemic pressure
Most often a secondary disease
-Chronic obstructive or interstitial lung disease
*Reduction in alveolar capillaries results in increased resistance
-Recurrent pulmonary emboli
*Reduces functional cross-section of pulmonary vasculature
-Heart disease
*Mitral stenosis, congenital left to right shunt
Primary or idiopathic pulmonary hypertension
-Most cases are sporadic (6% familial form)
Pulmonary Hypertension path
Pulmonary endothelial cell and/or smooth muscle dysfunction
In secondary pulmonary hypertension, endothelial cell dysfunction
-Reduced vasodilatory agents
-Increase vasoconstrictive mediators
-Induce replication of vascular smooth muscle and extracellular matrix elaboration
Pulmonary Hypertension clinical
Secondary PH may develop at any age
-Accentuation of respiratory insufficiency and right-sided heart strain
Primary PH is almost always in young persons, more commonly women
-Fatigue, syncope (particularly on exercise), dyspnea on exertion, and sometimes chest pain
-Develop severe respiratory insufficiency and cyanosis
-Death usually results from right-sided heart failure
-Survival is 2-5 years from diagnosis
Diffuse Alveolar Hemorrhage Syndromes
Immune related diseases that present with the triad of hemoptysis, anemia, and diffuse pulmonary infiltrates
Goodpasture syndrome
Idiopathic pulmonary hemosiderosis
Goodpasture syndrome
- Proliferative, usually rapidly progressive, glomerulonephritis and hemorrhagic interstitial pneumonitis
- Caused by antibodies targeted against collagen IV
- 90% have detectable serum antibodies
- Diffuse alveolar hemorrhage
- Linear pattern of immunoglobulin deposition along alveolar septa
- Treat with plasmapheresis and immunosuppressives
Idiopathic pulmonary hemosiderosis
Diffuse alveolar hemorrhage similar to Goodpasture syndrome but no renal involvement or anti-basement membrane antibodies
Mild to moderate course with periods of activity followed by prolonged remissions
Most cases are seen in children
Pulmonary Angiitis and Granulomatosis
Wegner granulomatosis
>80% of WG patients develop upper respiratory or lung involvement
Lung lesions
-Necrotizing vasculitis and parenchymal necrotizing granulomatous inflammation
-Pulmonary vessels may show necrotizing granulomas but most often acute and chronic inflammation with fibrinoid necrosis
Pulmonary Angiitis and Granulomatosis
Can have both upper respiratory and pulmonary symptoms
-Chronic sinusitis, epistaxis, nasal perforation
-Cough, hemoptysis, chest pain
Radiographically, multiple nodular densities (confluence of granulomas, some may cavitate)
While usually a multisystem disease, it may be restricted to the lung (“limited” WG)
Lung Tumors
Common site for metastatic disease
Primary lung cancer is also common
Primary lung tumors
-Bronchial epithelium; carcinomas (95%)
-Others (5%)
*Bronchial carcinoids, mesenchymal malignancies, lymphomas, benign lesions
*Hamartoma is the most common benign lesion
Spherical, small (3-4 cm), often appear as “coin” lesions
Carcinomas
1 cause of cancer related deaths in industrialized countries
-1/3 of cancer deaths in men in US
-Leading cause of cancer death in women since 1987
Causal link to cigarette smoking
Peak incidence: 50-70 years of age
At diagnosis,
-50% have distant metastatic disease
-25% have disease in regional lymph nodes
5 year survival rate
-All stages combined: 15%
-Localized to lung: 45%
Carcinomas Four major histological types
Squamous cell carcinoma
Adenocarcinoma
Small-cell carcinoma
Large-cell carcinoma
Combination patterns exist
Adenocarcinoma is now the most common type
Adenocarcinomas are by far the most common type in women, lifetime non-smokers, and younger than 45 years of age
For therapeutic purposes, lung carcinomas are divided into two broad groups
Small-cell lung cancer (SCLC)
Non-small-cell lung cancer (NSCLC)
Virtually all SCLC has metastasized at the time of diagnosis
Not curable by surgery
Treated by chemotherapy with or without radiation
NSCLC respond poorly to chemotherapy and are better treated by surgery
Genetic differences between SCLC and NSCLC
G1-S checkpoint is abrogated by different mechanisms
SCLC has high frequency of RB gene mutations
NSCLC commonly has inactivated p16/CDKN2A gene
Activating KRAS and EGFR mutations occur in adenocarcinomas
Carcinomas Etiology and pathogenesis
Arise by step-wise accumulation of genetic abnormalities that transform benign bronchial epithelium into neoplastic tissue
Predictable sequence that parallels histologic progression
-Inactivation of tumor suppressor genes on 3p is a very early event
-p53 mutations and KRAS activation occurs late
Subset of adenocarcinoma arising in non-smoking, Far-Eastern women has EGFR activation
Carcinomas
There is an impressive body of evidence that cigarette smoking causes lung cancer
-Squamous cell and small-cell carcinomas have the strongest association with tobacco exposure
Other environmental influences are associated with an increased incidence of lung cancer
-Miners of radioactive ores; asbestos workers; exposure to dusts containing arsenic, chromium, uranium, nickel, vinyl chloride, mustard gas
Carcinomas morphology
Usually begin as small mucosal lesions
May form intraluminal masses, invade the bronchial mucosa, or push into the lung parenchyma
Large masses may undergo central necrosis, hemorrhage, or cavitation
May extend to pleura and invade the pleural cavity, chest wall, or adjacent intrathoracic structures
May spread by lymphatic or hematogenous routes